Genmab Says Rina-S Shows Significant PFS and Overall Survival Improvement
Genmab announced positive topline Phase 3 results for rinatabart sesutecan in patients with platinum-resistant ovarian cancer.
Genmab A/S (NASDAQ:GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistan…